Kuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law Firm

▤ Summary

Kuehn Law says it is investigating Inovio Pharmaceuticals and its officers and directors for possible breaches of fiduciary duty. The complaint centers on alleged misstatements and omissions about manufacturing deficiencies for the CELLECTRA device and delayed regulatory timing for INO-3107. The notice says the company may have overstated the drug’s regulatory and commercial prospects. Shareholders who owned INO before October 10, 2023 are invited to contact the firm. This is a legal and governance matter tied to a life sciences company, not a software launch or corporate transaction.

▦ Linked Companies